CRBU241220C500
- 0.00
- 0.000.00%
Caribou Biosciences Newsroom
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Caribou Biosciences Analyst Ratings
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Cuts Target Price to $6
Express News | Caribou Biosciences Inc : Citigroup Cuts Target Price to $6 From $30
Caribou Biosciences Reports Q3 2024 Financial Results
Caribou Biosciences to Participate in Upcoming Investor Conferences
H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9
Express News | HC Wainwright & Co. Reiterates Buy on Caribou Biosciences, Maintains $9 Price Target
Analysts Are Updating Their Caribou Biosciences, Inc. (NASDAQ:CRBU) Estimates After Its Third-Quarter Results
Caribou Biosciences' Strategic Advancements and Financial Efficiency Bolster Buy Rating
Evercore Maintains Caribou Biosciences(CRBU.US) With Hold Rating, Maintains Target Price $3
Caribou Bioscience GAAP EPS of -$0.38 Beats by $0.06, Revenue of $2.02M Misses by $1.07M
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates
Caribou Biosciences | 10-Q: Q3 2024 Earnings Report
Caribou Biosciences | 8-K: Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Express News | Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Press Release: Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
CRISPR Technology Market Report 2024, With Profiles of Major Players Agilent Technologies, Beam Therapeutics, Caribou Biosciences, Crispr Therapeutics, Danaher, Genscript, Lonza and More - ResearchAndMarkets.com
Caribou Biosciences, Inc. (NASDAQ:CRBU) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Caribou Wins Pilot Competition With Right at Home, Becoming National Preferred Partner for Rewards & Recognition Across the United States